Scri Development Innovations, Llc
Clinical trials sponsored by Scri Development Innovations, Llc, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for advanced colon cancer: drug combo trial launches Results expected Jan 2027 (estimated)
- Myeloma drugs tested for home use: could cut hospital stays Results expected Aug 2027 (estimated)
-
Could a simple shot replace hospital stays for myeloma patients?
Disease control Recruiting nowThis study tests whether the drug elranatamab can be given safely in an outpatient clinic instead of the hospital for people with multiple myeloma that has come back or stopped responding to treatment. About 46 adults will receive the drug along with a single preventive dose of a…
Phase 2 • Sponsor: SCRI Development Innovations, LLC • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for advanced colon cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs (fruquintinib and FOLFIRI) in people with advanced colorectal cancer that has spread. It is for those who have already had one prior treatment. The goal is to see if this new combination can help control the cancer longer and with manag…
Phase 2 • Sponsor: SCRI Development Innovations, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug combo challenges stem cell transplant in multiple myeloma trial
Disease control Recruiting nowThis study tests whether a combination of two drugs (elranatamab and daratumumab) can work as well as or better than a stem cell transplant for people newly diagnosed with multiple myeloma. About 100 adults who have already had initial treatment will be randomly assigned to one o…
Phase 2 • Sponsor: SCRI Development Innovations, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Myeloma drugs tested for home use: could cut hospital stays
Disease control Recruiting nowThis phase 2 trial is testing whether two drugs, teclistamab and talquetamab, can be given safely in an outpatient setting for people with multiple myeloma. The study will enroll 100 participants who have already tried other treatments. The main goal is to see how often side effe…
Phase 2 • Sponsor: SCRI Development Innovations, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug pair aims to shrink Hard-to-Treat breast tumors
Disease control Recruiting nowThis study is for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. It tests two drugs together: tucatinib and Doxil. The goal is to see how well the combination shrinks tumors and to track any side effects. About 36 adults will take part.
Phase 2 • Sponsor: SCRI Development Innovations, LLC • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC